Insider Trading Alert - SANW, STRZA And SCLN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 26, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $232.50 to $546,600,000.00.

Highlighted Stocks Traded by Insiders:

S&W Seed Company (SANW) - FREE Research Report

Smith William S, who is Director at S&W Seed Company, bought 10,000 shares at $4.30 on May 26, 2015. Following this transaction, the Director owned 50,000 shares meaning that the stake was boosted by 25% with the 10,000-share transaction.

The shares most recently traded at $4.45, up $0.15, or 3.29% since the insider transaction. Historical insider transactions for S&W Seed Company go as follows:

  • 4-Week # shares bought: 2,954
  • 4-Week # shares sold: 50,000
  • 12-Week # shares bought: 2,954
  • 12-Week # shares sold: 50,000
  • 24-Week # shares bought: 2,954
  • 24-Week # shares sold: 50,000

The average volume for S&W Seed Company has been 85,400 shares per day over the past 30 days. S&W Seed Company has a market cap of $58.4 million and is part of the consumer goods sector and food & beverage industry. Shares are up 11.5% year-to-date as of the close of trading on Tuesday.

S&W Seed Company engages in breeding, growing, processing, and selling agricultural commodities in the Western United States, Mexico, South America, the Middle East, and Africa, as well as in other countries with Mediterranean climates. Currently, there are 5 analysts who rate S&W Seed Company a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SANW - FREE

TheStreet Quant Ratings rates S&W Seed Company as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and a generally disappointing performance in the stock itself. Get the full S&W Seed Company Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Starz (STRZA) - FREE Research Report

Wiesenthal Robert S, who is Director at Starz, sold 3,000 shares at $41.00 on May 26, 2015. Following this transaction, the Director owned 10,971 shares meaning that the stake was reduced by 21.47% with the 3,000-share transaction.

The shares most recently traded at $41.23, up $0.23, or 0.55% since the insider transaction. Historical insider transactions for Starz go as follows:

  • 4-Week # shares sold: 4,355
  • 12-Week # shares sold: 64,020
  • 24-Week # shares sold: 89,515

The average volume for Starz has been 889,900 shares per day over the past 30 days. Starz has a market cap of $3.8 billion and is part of the services sector and media industry. Shares are up 38.55% year-to-date as of the close of trading on Tuesday.

Starz, through its subsidiaries, operates as a media and entertainment company. It operates through Starz Networks, Starz Distribution, and Starz Animation segments. The Starz Networks segment provides premium subscription video programming to U.S. The company has a P/E ratio of 15.4. Currently, there are 4 analysts who rate Starz a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STRZA - FREE

TheStreet Quant Ratings rates Starz as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow. Get the full Starz Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

SciClone Pharmaceuticals (SCLN) - FREE Research Report

Hawkins Richard J, who is Director at SciClone Pharmaceuticals, sold 15,682 shares at $9.51 on May 26, 2015. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 15,682-share transaction.

The shares most recently traded at $9.43, down $0.08, or 0.8% since the insider transaction. Historical insider transactions for SciClone Pharmaceuticals go as follows:

  • 4-Week # shares sold: 18,727
  • 12-Week # shares sold: 26,530
  • 24-Week # shares sold: 42,121

The average volume for SciClone Pharmaceuticals has been 419,600 shares per day over the past 30 days. SciClone Pharmaceuticals has a market cap of $468.2 million and is part of the health care sector and drugs industry. Shares are up 7.99% year-to-date as of the close of trading on Tuesday.

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the United States, and Hong Kong. The company has a P/E ratio of 16.6. Currently, there are no analysts who rate SciClone Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCLN - FREE

TheStreet Quant Ratings rates SciClone Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full SciClone Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric